Submission of Un-Audited Financial Results for the Quarter ended on June 30th 2026 and along with Limited Review Report Thereon.

J O H N S O N PHARMACARE LIMITED CIN: L51100GJ1994PLC022388 Registered & Corp. Office Address - I-460, Fourth Floor, Titanium City Centre Mall, Near Sachin Tower, Anand Nagar Road, Satellite, Ahmedabad-380015 Email id: johnsonpharmacare1994@gmail.com sunandshineworldwideltd@gmail.com Date: 13.08.2026 The Department of Corporate Service BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400001. SCRIP CODE: 532154 (JOHNSON PHARMACARE LTD) EQ - ISIN - INE560F01022 Sub: Submission of Un-Audited financial results of (JOHNSON PHARMACARE LTD) for the quarter ended on June 30th, 2026 and along with Limited Review Report thereon. Dear Sir/Madam (s), Pursuant to Regulation 33 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose hereto, for your information and record: 1. The Un-Audited financial results of JOHNSON PHARMACARE LTD (“the Company”) for the quarter ended on June 30th, 2026, duly approved by the Board of Directors of the Company at its meeting held today, i.e. on Thursday August 13th, 2026 (which was commenced at 05:00 P.M. and concluded at 05:30 P.M.) 2. Limited Review Report dated 13th August, 2026 issued by the Statutory Auditors of the Company M/S V R S K & ASSOCIATES, on the aforesaid financial results of the Company for the quarter ended on June 30th, 2026 which was duly placed before the Board at the aforesaid meeting. You are requested to take the above on your records and acknowledge the same. For and on behalf of Board of Directors JOHNSON PHARMACARE LIMITED Nand Kishor Ray Additional Director DIN: 11626638 Date: 13-08-2026 Place: Gujrat Encl: As attached (ft( VRSK & ASSOCIATES Chartered Accountants IN D I A Limited Review Report Review repott to Board of Directors of JOHNSON PHARMACARE LIMITED LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30'1''', 2026 OF JOHNSON PIIARMACARE LIMITED. We have reviewed the accompanying statement of unaudited Standalone Financial Results of JOHNSON PHARMACARE LIMITED for the quatter ended 30.06.2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a repott on these financial statements based on our review. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (India Accounting Standards) Rules, 2015 and the circular is the responsibility ofthe Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chattered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of any material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, subject to the matter given in Emphasis of matter we are of the opinion that the accompanying statement of unaudited standalone financial results, which have not been prepared in accordance with applicable accounting standards i.e. IND AS prescribed under Section 133 ofthe Companies Act, 2013 read with relevant rules issued thereunder. However, nothing has come to our attention which causes us to believe that the accompanying statement of unaudited standalone financial results do not disclosed the information required to be disclosed ins terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 0511 • July, 2016, or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies including the manner in which it is to be disclosed, or that it contains any material misstatement. Partner New Delhi, August 13, 2026 UDIN: 26089823QIJLlK3495 Head Office Faridabad Office South Deihl Office Dwarka Office RohlnlOffice 42, Ward No,18, Basti 173, Sector 21A H1555, LGF, F-6 Malik Building-1 Plot No H-19/53, Pura, Arya Nagar, Rohtak- Faridabad, 121001, Chittaranjan Park, 2 Pocket 6 Sector, Dwarka Sector-7, Rohini, 124001, Haryana, Haryana New Delhi-llOO19 New Delhi-l10075, Delhi-110085 Ph. +91.9310203089 Ph . +919350695696 Ph. +919811022855 Ph. +919811042128 Ph.+91.9310203089 casmittal@gmail,com vrsk.o ffice@gm ail ,com vineet@vrskca ,com ankushfca@gmail.com rrjc_delhi@yahoo. co.in